Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 13/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 13/20 | 0.56 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | P4HB | P07237 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656090 | 0.85 | CNR1 (0.43) | MKNK1MKNK2KMOCYP2A6ERN1 | |
| SCHEMBL12675733 | 0.83 | MKNK1 (0.53) | MKNK1MKNK2KMOMEN1PSIP1 | |
| SCHEMBL3092733 | 0.81 | MAPT (0.58) | MKNK1MKNK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL5654037 | 0.80 | PIM2 (0.67) | KMOPIM1PIM2P4HBCYP11B2 | |
| SCHEMBL29569162 | 0.80 | ERN1 (0.57) | MKNK1MKNK2KMOMEN1PSIP1 | |
| SCHEMBL958907 | 0.80 | ERN1 (0.57) | MKNK1MKNK2KMOMEN1PSIP1 | |
| SCHEMBL30584113 | 0.78 | PIM2 (0.68) | KMOCYP1A2CYP3A4PIM2P4HB | |
| SCHEMBL28509453 | 0.78 | PIM2 (0.68) | KMOCYP1A2CYP3A4PIM2P4HB | |
| SCHEMBL12676020 | 0.78 | PLCG1 (0.58) | MEN1ALDH1A1CYP1A2 | |
| SCHEMBL5849078 | 0.77 | CYP2A6 (0.45) | MKNK1MKNK2CYP2A6ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135472-B2 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | claimed |
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-7135472-B2 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-7091202-B2 | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060063790-A1 | 4-Arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063790-A1 | 4-Arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators | KCNQ2, KCNQ1, KCNQ4 | MKNK1 1968/4885MKNK2 2157/4885KMO 195/4885 |
| US-20040106621-A1 | 3-Heterocyclic benzylamide derivatives as potassium channel openers | KCNQ3, KCNQ5, KCNQ2 | MKNK1 3242/4885MKNK2 3000/4885KMO 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.